An Open Label Dose-Escalation Study Of A Self Complementary Adeno-Associated Viral Vector (scAAV 2/8-LP1-hFIXco) For Gene Transfer in Hemophilia B

Trial Profile

An Open Label Dose-Escalation Study Of A Self Complementary Adeno-Associated Viral Vector (scAAV 2/8-LP1-hFIXco) For Gene Transfer in Hemophilia B

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Jul 2017

At a glance

  • Drugs AAV-hFIX (Primary)
  • Indications Haemophilia B
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jul 2017 Status changed from recruiting to active, no longer recruiting.
    • 09 Nov 2016 Planned End Date changed from 1 Jul 2031 to 1 Dec 2032.
    • 09 Nov 2016 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top